A Feasibility and Safety Study of Vaccination With Poly-ICLC and Peptide-pulsed Dendritic Cells in Patients With Metastatic, Locally Advanced, Unresectable, or Recurrent Pancreatic Adenocarcinoma

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

August 31, 2011

Primary Completion Date

November 30, 2013

Study Completion Date

May 31, 2015

Conditions
Metastatic Pancreatic Cancer
Interventions
DRUG

vacc. w/ Poly-ICLC & peptide-pulsed dendritic cells

Intradermal injection of 1x107 peptide-pulsed dendritic cells followed by intramuscular injection of 30 micrograms per kilogram Poly-ICLC on days 0, 14, 28 and 42. Additional dose of 30 micrograms per kilogram Poly-ICLC on days 3, 17, 31 and 45. Treatment given via one 56-day cycle. Leukapheresis performed at baseline for dendritic cell generation.

Trial Locations (1)

29425

Medical University of South Carolina, Charleston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Oncovir, Inc.

INDUSTRY

lead

Carolyn Britten

OTHER